Showing 1191-1200 of 7529 results for "".
Scientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.Are Exosomes the Next Big Thing?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/are-exosomes-the-next-big-thing/20090/Dr. Farris, co-founder (with Dr. Ted Lain) of the Science of Skincare Summit, summarizes key points from her recent article on exosomes and their potential applications for topical skincare? Are they the next big thing? Watch to find out!Finally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."Scientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PAn Excellent Networking Opportunity: DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/an-excellent-networking-opportunity-derm2021/19963/From opportunities to connect and network with other NPs and PAs to going to sessions presented by some of her favorite dermatologists, such as Ted Rosen, MD, to learn about what’s in the pipeline and coming to market soon, Leigh Ann Pansch, MSN, FNP-BC, DCNP is excited to attend the DERM2021 NP/PANew and Emerging Therapies Target Improved Patient Experiences
https://practicaldermatology.com/topics/psoriasis/new-and-emerging-therapies-target-improved-patient-experiences/23504/Updates from the AAD VMX 2021.The Expanding Role for PD-1 Inhibitors for NMSCs
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-expanding-role-for-pd-1-inhibitors-for-nmscs/19937/The pool of potential patients that could be treated with PD-1 inhibitors is growing. Todd Schlesinger, MD discusses how these drugs may be used to treat a greater number of patients with NMSCs and addresses side effects and their management.The Time is Now: Dermatology and Climate Change
https://practicaldermatology.com/topics/practice-management/the-time-is-now-dermatology-and-climate-change/19930/How are global warming and associated changes in weather affecting the presentation of skin diseases? And what opportunities do dermatologists have to help turn the tide of global warning? Misha Rosenbach, MD reviews the science and touches on opportunities for change.Get The Word Out: Branding Plus Online Presence Equals Reputation Building
https://practicaldermatology.com/topics/practice-management/get-the-word-out-branding-plus-online-presence-equals-reputation-building/23441/Your online branding program and associated initiatives can improve your web ranking and your appeal to patients.